Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - midazolam hydrochloride, quantity: 1.112 mg/ml (equivalent: midazolam, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time; iv for sedation in intensive care units; intermittent administration or continuous infusion; im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - midazolam hydrochloride, quantity: 1.112 mg/ml (equivalent: midazolam, qty 1 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time; iv for sedation in intensive care units; intermittent administration or continuous infusion; im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

United States - English - NLM (National Library of Medicine)

hospira, inc. - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection is indicated: injectable midazolam is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam; patients with glaucoma have not been studied. midazolam injection contains midazolam a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs. midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam. withdrawal symptoms, similar in ch

United States - English - NLM (National Library of Medicine)

hospira, inc. - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection is indicated: injectable midazolam is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam; patients with glaucoma have not been studied. midazolam injection contains midazolam a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs. midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam. withdrawal symptoms, similar in ch

United States - English - NLM (National Library of Medicine)

henry schein, inc. - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection is indicated: - intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; - intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; - intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); - continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting. injectable midazolam is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam; patients with glaucoma have not been studied. midazolam injection contains midazolam a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs. midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, hallucinations, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuation of benzodiazepines, including midazolam. abdominal distention, nausea, vomiting, and tachycardia are prominent symptoms of withdrawal in infants. the more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. there is no consensus in the medical literature regarding tapering schedules; therefore, practitioners are advised to individualize therapy to meet patient's needs. in some case reports, patients who have had severe withdrawal reactions due to abrupt discontinuation of high-dose long-term midazolam, have been successfully weaned off of midazolam over a period of several days.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection, usp is indicated: injectable midazolam hydrochloride is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam hydrochloride; patients with glaucoma have not been studied. midazolam hydrochloride is not intended for intrathecal or epidural administration due to the presence of the preservative benzyl alcohol in the dosage form. midazolam hydrochloride is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see warnings and precautions, pediatric use ). midazolam hydrochloride contains midazolam, a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive

United States - English - NLM (National Library of Medicine)

a-s medication solutions - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection, usp is indicated: injectable midazolam hydrochloride is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam hydrochloride; patients with glaucoma have not been studied. midazolam hydrochloride is not intended for intrathecal or epidural administration due to the presence of the preservative benzyl alcohol in the dosage form. midazolam hydrochloride is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see warnings and precautions, pediatric use ). midazolam hydrochloride contains midazolam, a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive

United States - English - NLM (National Library of Medicine)

micro labs limited - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection is indicated: - intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; - intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; - intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); - continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting. injectable midazolam is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam; patients with glaucoma have not been studied. midazolam injection contains midazolam a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs. midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, hallucinations, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuation of benzodiazepines, including midazolam. abdominal distention, nausea, vomiting, and tachycardia are prominent symptoms of withdrawal in infants. the more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. there is no consensus in the medical literature regarding tapering schedules; therefore, practitioners are advised to individualize therapy to meet patient's needs. in some case reports, patients who have had severe withdrawal reactions due to abrupt discontinuation of high-dose long-term midazolam, have been successfully weaned off of midazolam over a period of several days.

United States - English - NLM (National Library of Medicine)

atlantic biologicals corp. - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam hcl syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. midazolam hcl syrup is intended for use in monitored settings only and not for chronic or home use (see warnings). midazolam is contraindicated in patients with a known hypersensitivity to the drug or allergies to formulation excipients. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction of general anesthesia with injectable midazolam; patients with glaucoma have not been studied. midazolam hcl syrup is a benzodiazepine and is a schedule iv controlled substance that can produce drug dependence of the diazepam-type. therefore, midazolam hcl syrup may be subject to mis

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam hcl syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. midazolam hcl syrup is intended for use in monitored settings only and not for chronic or home use (see warnings). midazolam is contraindicated in patients with a known hypersensitivity to the drug or allergies to formulation excipients. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction of general anesthesia with injectable midazolam; patients with glaucoma have not been studied. midazolam hcl syrup is a benzodiazepine and is a schedule iv controlled substance that can produce drug dependence of the diazepam-type. therefore, midazolam hcl syrup may be subject to mis